Systemic Toxicity With Use of Apraclonidine Ophthalmic Drops in Pediatric Patients

This case series suggests use of apraclonidine in pediatric patients poses a risk of central α-2 adrenergic agonist-induced central nervous system and respiratory depression. Clinicians who use apraclonidine in the pediatric population should be aware of potential serious systemic effects from ophthalmic use of the drug and be prepared to manage these.